Boyds is delighted to welcome Susan Tansey who joins the business as Consultant Pharmaceutical Physician.
Dr Tansey joins Boyds with more than 20 years’ experience in rare disease clinical trials. A paediatrician specialising in respiratory paediatrics and neonatology, Susan joined the pharmaceutical industry in 1998 and has worked in clinical development across several therapeutic areas, including vaccine research.
Previously, Susan was Vice President and Global Head of Therapeutic Strategy at IQVIA, where she was responsible for providing medical, clinical and scientific advisory expertise to the allergy, respiratory, infectious disease, vaccines and women’s health therapeutic areas, and managed a team of eight physicians.
Susan’s career has spanned various senior clinical development roles including Senior Medical Director Paediatrics at Premier Research Group Ltd, Associate Director for Industry at the UK National Institute of Health Research – Clinical Research Network – Children and Director of Medical Services at TMC Pharma Services.
A Member of the Royal College of Paediatrics and Child Health (RCPCH) and a Fellow of the Faculty of Pharmaceutical Medicine (FPM), Susan also holds the Membership of the Royal Colleges of Physicians (MRCPUK) qualification and has a Certificate of Completion of Specialist Training (CCST) in Pharmaceutical Medicine.
“I have known Professor Alan Boyd for many years through the Faculty of Pharmaceutical Medicine and was particularly interested in the ground-breaking gene therapy studies Boyds has recently been involved in.” Susan explains. “I am therefore very excited to have the opportunity to work with Alan and his team on clinical trials and consultancy work and use my expertise to complement the company’s service offering to clients.”
Boyds’ Founder and CEO, Professor Alan Boyd, adds: “Susan’s expertise in rare disease clinical trials will be of great benefit to our clients, as we continue to see an increase in work in the clinical trials space. With experience of clinical development in both pharmaceutical companies and CROs, Susan will add strength and depth to our clinical trials offering, as well as helping us to drive our plans for continued growth.”
